STOCKHOLM, May 8, 2025 /PRNewswire/ -- BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that regulatory authorities in Spain in Poland have approved the inclusion of Multiple System ...
Shares of Alterity Therapeutics ATHE were up 7.8% on Jul 17 after the company announced positive interim data from the phase II ATH434-202 study evaluating its lead pipeline candidate ATH434 for ...
Eye signs in patients with parkinsonism: do they predict the development of multiple system atrophy?
This Practice Point commentary discusses Anderson et al.'s study of oculomotor function in multiple system atrophy (MSA). After comparing their findings with those in other disorders, the authors ...
The goal is to develop a disease modifying treatment that stops or slow down the progression of alpha-synucleinopathies e.g. Parkinson's disease and MSA. BioArctic's phase 2a study EXIST with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results